Market Access/ News/ News FDA approves UCB’s Cimzia in plaque psoriasis Linda Banks Cimzia, dermatology, immuno-dermatology, psoriasis, skin condition, UCB 0 Comment The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis Share X FDA approves UCB’s Cimzia in plaque psoriasis https://pharmaphorum.com/news/fda-ucbs-cimzia-plaque-psoriasis/